Show simple item record Rider LG Aggarwal R Pistorio A Bayat N Erman B Feldman BM Huber AM Cimaz R Cuttica RJ de Oliveira SK Lindsley CB Pilkington CA Punaro M Ravelli A Reed AM Rouster-Stevens K van Royen-Kerkhof A Dressler F Magalhaes CS Constantin, Tamás Davidson JE Magnusson B Russo R Villa L Rinaldi M Rockette H Lachenbruch PA Miller FW Vencovsky J Ruperto N Int Myositis Assessment Clinical Paediat Rheumatology Int Trials 2022-06-20T13:04:15Z 2022-06-20T13:04:15Z 2017
dc.identifier.citation pagination=911-923; journalVolume=69; journalIssueNumber=5; journalTitle=ARTHRITIS & RHEUMATOLOGY;
dc.identifier.uri doi:10.1002/art.40060
dc.description.abstract OBJECTIVE: To develop response criteria for juvenile dermatomyositis (DM). METHODS: We analyzed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheumatology International Trials Organisation (PRINTO) and were derived from natural history data and a conjoint analysis survey. They were further validated using data from the PRINTO trial of prednisone alone compared to prednisone with methotrexate or cyclosporine and the Rituximab in Myositis (RIM) trial. At a consensus conference, experts considered 14 top candidate criteria based on their performance characteristics and clinical face validity, using nominal group technique. RESULTS: Consensus was reached for a conjoint analysis-based continuous model with a total improvement score of 0-100, using absolute percent change in core set measures of minimal (>/=30), moderate (>/=45), and major (>/=70) improvement. The same criteria were chosen for adult DM/polymyositis, with differing thresholds for improvement. The sensitivity and specificity were 89% and 91-98% for minimal improvement, 92-94% and 94-99% for moderate improvement, and 91-98% and 85-86% for major improvement, respectively, in juvenile DM patient cohorts using the IMACS and PRINTO core set measures. These criteria were validated in the PRINTO trial for differentiating between treatment arms for minimal and moderate improvement (P = 0.009-0.057) and in the RIM trial for significantly differentiating the physician's rating for improvement (P < 0.006). CONCLUSION: The response criteria for juvenile DM consisted of a conjoint analysis-based model using a continuous improvement score based on absolute percent change in core set measures, with thresholds for minimal, moderate, and major improvement.
dc.relation.ispartof urn:issn:2326-5191
dc.title 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative
dc.type Journal Article 2018-08-16T06:44:20Z
dc.language.rfc3066 en
dc.identifier.mtmt 3212916
dc.identifier.wos WOS:000400068300005
dc.identifier.pubmed 28382778
dc.contributor.department SE/AOK/K/II. Sz. Gyermekgyógyászati Klinika
dc.contributor.institution Semmelweis Egyetem
dc.mtmt.swordnote Erratum in: Arthritis Rheumatol. 2018 Mar;70(3):467. doi: 10.1002/art.40450 Párhuzamos közlés This article is published simultaneously in the May 2017 issue of Annals of the Rheumatic Diseases (MTMT-ben: 3341646)

Files in this item

This file is available only from Semmelweis network

This file is available only from Semmelweis network


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account